Insmed To Present Data Across Its Respiratory Portfolio, Including Late-Breaking ARIKAYCE® Results From Phase 3B ENCORE Study, At The American Thoracic Society International Conference 2026. -New Data ...
These findings are important because they suggest that more selective JAK inhibition, particularly targeting JAK1 or JAK2, can effectively reduce organ pathology and pathogenic IFN-γ-producing immune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results